Debiopharm

This page shows the latest Debiopharm news and features for those working in and with pharma, biotech and healthcare.

Merck and Roche team up for hepatitis C studies

Meanwhile, a range of other new HCV drugs are coming through the pharma industry's pipelines, including Novartis and Debiopharm's DEB025, Boehringer Ingelheim's BI 201335, Bristol-Myers Squibb 's

Latest news

More Eloxatin settlements for sanofi-aventis

Mayne/Hospira, MN/Par and Actavis have all settled outstanding litigation regarding certain formulations of Eloxatin, currently under licence by S-A and Debiopharm.
Sanofi-aventis settles Eloxatin lawsuits

medicine. S-A, who hold patent rights for the drug along with Swiss-based Debiopharm, did not give any other details regarding the recent settlements, including financial.
Novartis gain rights to hepatitis C drug

The Swiss drugmakers will make an undisclosed upfront payment to Debiopharm Group, an independent biopharmaceuticals company based in Switzerland, with Novartis receiving exclusive worldwide development and marketing rights (excluding Japan).
HCV hope on the horizon

The ciclosporin analogue DEBIO 025 (Debiopharm) is a first-in-class cyclophilin inhibitor that has been generally well tolerated in clinical trials to date and may have potential as an addition
Pandemic preparedness

Micombi (Nippon Boehringer Ingelheim, Astellas Pharma). Hypertension. Japan. Triptorelin. Salvacyl (Debiopharm).

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Pharma deals during January 2013

Debiopharm. Chugai. Licence. Exclusive worldwide licence to FF 284 in oncology.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Account Manager- Healthcare Advertising: Negotiable

Account Manager: Negotiable

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Principal Health Economist - North-West: Negotiable

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Director: Competitive Salary Offered

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Medical (Scientific) Director: £120, 000 benefits

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Senior Editorial Assistant – Greater Manchester: DOE

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Associate Director: £75, 000-90, 000

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Business Director: Competitive Salary Offered

Account Executive/ Senior Account Executive: competitive Salary Offfered

Associate Medical Director: Excellent PTO, bonus and 401k package

Business Development Director – Health Education: excellent commission

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Experienced Medical Writers: Competitive Salary and Benefits

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Systematic Reviewer - Oxford: Negotiable

Account Manager / Account Director: Competative

Subscribe to our email news alerts

PMHub

Add my company

Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...